Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.1MCash on Hand
1.6mo Cash Runway
Follow INM by emailGet an email when INM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INM, unsubscribe in one click. Privacy
📣 What INM Says Is Next
Q1 2027 · “MT-002 is on track for a regulatory filing in Q1 2027, with initial data expected by year-end 2027.”
Company press release, Nov 9, 2026 · SEC filing
mid-2027 · “MT-001, an investigational monoclonal antibody with potential for best-in-class efficacy and convenient, infrequent subcutaneous dosing, continues to advance in Phase 1 development with dosing ongoing and initial data expected mid-2027.”
Company press release, Nov 9, 2026 · SEC filing
fourth quarter of 2026 · “The transactions contemplated by the Merger Agreement are expected to close in the fourth quarter of 2026, subject to, among other things, shareholder approval.”
Company press release, Sep 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Deal InMed completed its redomestication to Nevada and a merger with Mentari, closing November 6, 2026. Mentari holders will own about 99.0% of the combined company, which is renamed Mentari Therapeutics, Inc., focused on migraine prevention. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Deal InMed Pharmaceuticals completed its merger with Mentari Therapeutics, which begins trading on Nasdaq as MTRI today, November 9, 2026. Closing followed about $490 million in gross private placement proceeds, with roughly 58.3 million shares outstanding. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Shareholder vote InMed changed its name to Mentari Therapeutics, Inc. and effected a 1-for-10 share consolidation, with new CUSIP 457637809, effective November 4, 2026. Shareholders approved the Nasdaq share issuance, redomestication to Nevada, and the 2026 stock and ESPP plans for the Merger with Mentari. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Shareholder vote InMed shareholders approved all nine proposals at the November 4, 2026 annual meeting, including the Nasdaq share issuance for the Mentari merger (97.295% for) and Nevada redomestication (88.825% for). The company completed a 1-for-10 share consolidation and changed its name to Mentari Therapeutics, Inc. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 3, 2026 ·
Earnings InMed reported Q1 fiscal 2027 net loss of $2,330,778 with cash of $1,094,488 at Sept 30, 2026, and said cash funds operations into mid-November. Shareholders' equity is negative $1,199,396; Nasdaq deadline to regain compliance is March 15, 2027. Form 8-K · SEC filing · Press release
Oct 28, 2026 ·
Shareholder vote Supplement sets the CVR record date as close of business November 5, 2026 for InMed's contingent value rights tied to the Mentari merger, so only holders of record on that date receive CVRs. Shares issued after that date, including merger shares, will not receive them. Form 424B3 · SEC filing
Oct 1, 2026 ·
Deal InMed and Mentari Therapeutics propose a merger in which InMed redomesticates from British Columbia to Nevada and Mentari becomes a wholly owned subsidiary. Mentari holders would receive about 2.0065 InMed shares per share, and a reverse split of 1-for-2 to 1-for-20 is planned before closing. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2023 · Phase 2 · Results Expected · INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
INM holds $1.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations,
an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 2 months +40
ATM program on file since Apr 2026 +15
Shelf registration (S-3, Mar 2026) +10
Going-concern doubt in the latest 10-Q +15The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.10-Q, Nov 2026
Share count +96% in a year +20
Raised after last reported balance sheet (Nov 2026) -10
Share count 5,493,735 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full INM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.